Updated 06:01 GMT, 29 Oct 2026 SPX 7,743.98 +0.28% NDX 29,813.16 +0.55% VIX 16.91 -3.48% GOLD 4,040.30 -0.28% CL 101.33 -1.41% BTC 80,120.34 -0.85%
NAS100 29,813 +0.55% S&P 7,744 +0.28% GOLD $4,040 −0.28% BTC $80,120 −0.85% VIX 16.91 −3.48% latest tape · as of 06:01 UTC
The Screen · Basic Materials · Agricultural Inputs

Corteva

CTVA · a US exchange · USD · Market cap $8.6B · 21,500 employees

Corteva, Inc.

PASS · Titan Ethical · score 90.0
11.33 USD

Price as of 28 Oct 2026Daily close, not a live quote

Screened 2026-10-28 · the tape above runs as of 06:01 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price11.33 USD at the 28 Oct 2026 close
  • Our ratingFair value, current read distribution
  • Ethical screenPasses, score 90.0 out of 100
  • OptionsOpen interest leans to puts (put/call 2.82)
  • Last reviewed28 Oct 2026 (1 days ago)

A summary of the dated readings below, not a live quote and not advice.

PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
11.8111.8113.58

What this means: price 11.33 against the desk's fair-value range, base estimate 11.81, over the last year.

Current read
Distribution ?
FAIR VALUE · screened 2026-10-28
  • Trend Distribution
  • Insiders no filings inside 60 days, left as found
  • Positioning political selling, disclosed 2026-09-17
  • Options put/call open interest 2.82, read 2026-10-28
  • Ethical passes the values gate
Price11.33 USD
Fair value11.81
Ethical score90.0/100
RatingFAIR VALUE
Our investment reviews on this name
2026-07-02Read Distribution77.03-85.3% to today ✓First review on file: Distribution

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its distribution label.

Corteva holds its Distribution at $11.33. Consolidating, no directional conviction, held for 16 days.

As held on the ledger · 2026-10-28
PhaseDistribution · caution
Quantitative stateConsolidating, no directional conviction, held for 16 days
Price at the screen$11.33
Valuation7.95 trailing · 11.38 forward price to earnings
Values screenPASS · score 90.0
The Workings

Five Screens, Shown in Full

Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.

TestFigureLimitWhat it meansStatus
Business activity Permissible Core business clean Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
Debt load 6.02% Below 33% Interest-bearing debt is just 6.0% of its assets, well under the one-third ceiling: it does not run on borrowed money. Pass
Interest-bearing cash 0.37% Below 33% Cash held in interest-bearing accounts and securities is 0.4% of assets, under the one-third limit. Pass
Receivables 22.30% Below 49% Money owed to the company is 22.3% of assets, under the 49% limit. Pass
Revenue purity 0.78% Below 5% Only 0.8% of revenue comes from non-compliant sources, under the 5% line. Pass

Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.

The Ethical Read

Why It Clears, in Plain English

Corteva clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 6%, inside the ~33% line, and almost none of its income is interest, so it passes.

Read as at 2026-10-28. It updates when the underlying figures move, and past reads are kept below.

Follow this verdict

Get an email when CTVA's ethical verdict changes

Today CTVA passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Our analysis reads FAIR VALUE: it trades at roughly a 4% discount to our $11.81 fair value, narrow competitive moat.

11.81Conservative11.81Base case13.58Growth case 11.33Price

Fair value range in USD, drawn from the 2026-10-28 screen. The gold marker is the market price at the same screen. A 4.2% margin of safety to the base estimate.

The Street's Range
13.65Street low 17.00Street average 20.00Street high 11.33Price

Third-party analyst targets: 11 covering, consensus Buy. The average target sits +50% from the screen price.

Reading the gap · Both our model and the analysts see meaningful upside from here.

Price History & Projections
$89.4$47.7$6.1TODAY5y agoPROJECTIONStreet high$20.00 -73%Street avg$17.00 -77%Conservative$11.81 -84%Our fair value$11.81 -84%

Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-28 screen.

Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.

The Business, in Plain Words

Seeds and sprays priced for perfect harvests

Picture a farmer locking in next season's seed at a fat premium while the weather, pests and grain prices stay wild cards. Corteva sits in that spot right now. At 21 times forward earnings the shares trade well above our fair value with a negative margin of safety, and the narrow moat plus low single-digit ROE give little cushion when cycles turn.

The business splits between seeds and crop protection, both tied to farm incomes that swing with commodity prices and weather. Revenue growth looks solid at 11 percent, yet a 6 percent profit margin and 5 percent return on equity hardly scream durable advantage in a cyclical field. Analysts may cluster around a buy rating, but the valuation already prices in smooth sailing.

Cyclical names often flash cheap multiples at peak earnings; here the multiple is not cheap and the earnings can still fall fast. Currency moves, regulation on crop chemicals and sudden drops in planted acres all sit outside management control. Analysis, not advice.

The fundamentals · plain-English read
Forward P/E11.4xreasonably valued
Trailing P/E8.0xvery cheap relative to earnings
EPS, trailing1.62
EPS, forward1.13
Revenue growth-1.2%revenue is shrinking
Profit margin2.8%barely profitable
Dividend yield0.86%
Debt to equity0.57moderate, manageable leverage
Current ratio1.79healthy short-term liquidity
Short interest, float0.04%
52-week range9.08 - 14.62
MoatNARROW
Market cap$8.6B
Employees21,500

The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.

Plain-English interpretation of our own screen data. Analysis, not advice.

Where & How to Trade

CTVA trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-10-28 Distribution $12.88 +0.0% Entry 9

The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (21 analysts) rates it buy, with a mean price target of $89.

2026-10-21 Distribution $12.88 -83.6% Entry 8

The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 83.6% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (21 analysts) rates it buy, with a mean price target of $89.

2026-10-14 Distribution $78.52 +0.0% Entry 7

The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (21 analysts) rates it buy, with a mean price target of $89.

2026-10-02 Distribution $78.52 -1.2% Entry 6

Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 1.2% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (21 analysts) rates it buy, with a mean price target of $89.

2026-08-26 Distribution $79.46 -9.0% Entry 5

Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 9.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (21 analysts) rates it buy, with a mean price target of $89.

2026-07-25 Distribution $87.30 +13.3% Entry 4

Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 13.3% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (21 analysts) rates it buy, with a mean price target of $89.

2026-07-18 Distribution $77.03 +0.0% Entry 3

Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (21 analysts) rates it buy, with a mean price target of $89.

2026-07-03 Distribution $77.03 +0.0% Entry 2

Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score (90). The risk-adjusted return profile shows good risk-adjusted returns.

2026-07-02 Distribution $77.03 Entry 1

Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with near-perfect ethical score (90). The risk-adjusted return profile shows good risk-adjusted returns.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

Latest News · What the Market Is Reading on CTVA

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in CTVA's Space

Screened names in the same industry · explore each on its own page.

The Insider Ledger · Form 4 Filings, As Filed
Most recent filings · CTVA
DateInsiderTitleTypeSharesValue
2026-04-30 GIESSELMAN JANET PLAUT Director 95 $7,750
2026-04-30 NAYYAR NAYAKI R Director 401 $32,500
2026-04-28 GIESSELMAN JANET PLAUT Director 2,350 ·
2026-04-28 PAGE GREGORY R Director 3,870 ·
2026-04-28 EVERITT DAVID C Director 2,350 ·
2026-04-28 WARD PATRICK J Director 2,350 ·
2026-04-28 PREETE KERRY J Director 2,350 ·
2026-04-28 POLICINSKI CHRISTOPHER J Director 2,350 ·
2026-04-28 LUTZ MARCOS M Director 2,350 ·
2026-04-28 NAYYAR NAYAKI R Director 2,350 ·

Public filings, recorded as found. The full tape lives at Insider Intelligence.

The Political Ledger · Congressional Disclosures
Disclosures naming CTVA
DatePoliticianPartyTypeAmount
2026-09-17 Gil Cisneros Democrat sell 1K–15K
2026-09-17 Gil Cisneros Democrat sell 1K–15K
2026-09-04 Ro Khanna Democrat buy 1K–15K
2026-09-04 Ro Khanna Democrat buy 1K–15K
2026-05-15 Ro Khanna Democrat sell 1K–15K
What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $82.64 -9.1% $0.18 $912 -8.8%
2 months $83.64 -10.1% $0.18 $901 -9.9%
3 months $79.57 -5.5% $0.18 $947 -5.3%
6 months $65.74 +14.3% $0.36 $1,149 +14.9%
1 year $70.86 +6.1% $0.72 $1,071 +7.1%
2 years $50.66 +48.4% $1.40 $1,511 +51.1%
3 years $54.61 +37.6% $2.04 $1,414 +41.4%
5 years $42.19 +78.1% $3.20 $1,857 +85.7%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever CTVA does next, these words stay.

Corteva · CTVA · Distribution · $11.33
Recorded 2026-10-28 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.